NEW YORK, Sept. 12, 2025 /PRNewswire/ -- An affiliate of the fund known as EQT VIII ("EQT") is pleased to announce the completion of an underwritten public offering (the "Offering") of c. 18.0 million shares of common stock of Waystar Holding Corp. (NASDAQ: WAY) (the "Company") ("Shares"), for aggregate proceeds of c. USD 705.8 million to all the selling stockholders. As part of the Offering, EQT sold c. 7.8 million Shares (and now holds c. 24.9 million Shares) and received proceeds of c. USD 304.5 million. The remaining Shares sold in the Offering were sold by other stockholders of the Company. J.P. Morgan Securities LLC acted as underwriter of the Offering, which was completed on September 12, 2025. The Company did not sell any Shares in the Offering and did not receive any proceeds from the sale of the Shares sold by EQT and the other stockholders.
Contact
EQT Press Office, This email address is being protected from spambots. You need JavaScript enabled to view it.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press Release, EQT VIII, Waystar, 120925 |
| Last Trade: | US$32.99 |
| Daily Change: | 0.05 0.15 |
| Daily Volume: | 751,061 |
| Market Cap: | US$6.310B |
December 29, 2025 October 29, 2025 October 01, 2025 September 10, 2025 September 09, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
